Patents by Inventor Vladimir Cmiljanovic

Vladimir Cmiljanovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066116
    Abstract: This invention describes a fully synthetic, long-chain nucleic acid that can be used in biotechnological manufacturing processes to produce envelope proteins, virus envelopes and fragments of virus envelopes of SARS-CoV-2 and related coronaviruses in highly purified form, which, as a vaccine protect against COVID-19 and other viral diseases
    Type: Application
    Filed: September 9, 2021
    Publication date: February 29, 2024
    Applicant: ROCKETVAX AG
    Inventors: Matthias CHRISTEN, Natasa CMILJANOVIC VRANIC, Vladimir CMILJANOVIC
  • Publication number: 20220153752
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 19, 2022
    Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
  • Patent number: 11186591
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: November 30, 2021
    Assignees: UNIVERSITÄT BASEL, TORQUR AG
    Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Florent Beaufils, Thomas Bohnacker, Denise Rageot, Alexander Sele, Matthias Wymann, Jean-Baptiste Langlois
  • Publication number: 20200277304
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 3, 2020
    Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
  • Patent number: 10640516
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 5, 2020
    Assignees: PIQUR THERAPEUTICS AG, UNIVERSITÄT BASEL
    Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Florent Beaufils, Thomas Bohnacker, Denise Rageot, Alexander Sele, Matthias Wymann, Jean-Baptiste Langlois
  • Publication number: 20190031682
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Application
    Filed: November 10, 2015
    Publication date: January 31, 2019
    Inventors: Vladimir CMILJANOVIC, Paul HEBEISEN, Florent BEAUFILS, Thomas BOHNACKER, Denise RAGEOT, Alexander SELE, Matthias WYMANN, Jean-Baptiste LANGLOIS
  • Patent number: 9556203
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 31, 2017
    Assignees: PIQUR THERAPEUTICS AG, UNIVERSITAET BASEL
    Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Eileen Jackson, Florent Beaufils, Thomas Bohnacker, Matthias Wymann
  • Publication number: 20160244463
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Eileen Jackson, Florent Beaufils, Thomas Bohnacker, Matthias Wymann
  • Patent number: 8921361
    Abstract: The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds^ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: December 30, 2014
    Assignee: University of Basel
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Publication number: 20130040912
    Abstract: The invention relates to compounds of formula (I) R1 is methyl, n-hexyl, aminoethyl, methylaminoethyl, ethylaminoethyl, dimethylaminoethyl, acryloylaminoethyl, methacryloylaminoethyl, methoxyethyl, ethoxyethyl, d-C4-alkyl-sulfonyl, acryloyl, or methacryloyl; or R1 is aminoethyl, acryloyl or acryloylaminoethyl carrying a linker and a tag, and R2 and R3, independently of each other, are hydrogen or CrC4-alkyl, or R2 and R3 together form a methylene or an ethylene bridge; and tautomers, solvates and pharmaceutically acceptable salts thereof. These compounds are effective in preventing or treating a disease or disorder modulated by PI3 kinases and/or mTOR, in particular treating a hyperproliferative disorder.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 14, 2013
    Applicant: UNIVERSITY OF BASEL
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Publication number: 20130040934
    Abstract: The invention relates to new triazines (G=Q=U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4, CH2CH2, NR4, NR4?0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.
    Type: Application
    Filed: March 11, 2011
    Publication date: February 14, 2013
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Publication number: 20110275762
    Abstract: The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds? Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 10, 2009
    Publication date: November 10, 2011
    Applicant: UNIVERSITY OF BASEL
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann